Pre-exposure of CD26+ LSC to vildagliptin was limited their engraftment in mice [32], although another study found no effect of vildagliptin on CML engraftment (± imatinib) when mice were treated in vivo [39]. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.